Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

This study will evaluate the immunogenicity of GSK's trivalent MMR vaccine (referred to as INV\_MMR vaccine) in contrast to the US standard of care (M-M-R®II, Merck and Company, referred to as COM\_MMR) when both are used as a second dose in subjects 7 years of age and older. In this study, the INV\_MMR vaccine may be administered as a second dose to persons with either a history or formal documentation of at least one dose immunization with any MMR vaccine. This study is intended to support licensure of GSK's MMR vaccine in the US.